Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.61 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28463831 | 0.84 | CYP1A1 (0.67) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL12171494 | 0.84 | CYP1A1 (0.67) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL28337714 | 0.83 | NFE2L2 (0.50) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL18044446 | 0.82 | CYP1A1 (0.59) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL245504 | 0.82 | ALDH1A1 (0.63) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL28823895 | 0.80 | ALDH1A1 (0.61) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL17821645 | 0.79 | CYP1A2 (0.65) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL17821642 | 0.79 | CYP1A2 (0.65) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL24434458 | 0.77 | CYP1A2 (0.63) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 | |
| SCHEMBL18502970 | 0.77 | AMY1A (0.59) | CYP1A1CYP1A2CYP1B1AMY1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858641-B2 | melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-7858631-B2 | Substituted pyrido [2,3-d] pyrimidinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| EP-1551834-B1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-08-25 | — | — | EP | claimed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | claimed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-7470701-B2 | Substituted 2,5-heterocyclic derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | claimed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | claimed |
| JP-2007511612-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1551834-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050124652-A1 | Guanidino compounds | BOYCE RUSTUM (US) | 2005-06-09 | — | — | US | claimed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | claimed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1478626-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040019049-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2004-01-29 | — | — | US | claimed |
| WO-2003099818-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2003-12-04 | — | — | WO | claimed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | claimed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | CYP1A1 1761/4885CYP1A2 2636/4885CYP1B1 2743/4885 |
| US-20030195187-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | CYP1A1 3026/4885CYP1A2 3707/4885CYP1B1 3647/4885 |
| US-20040019049-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | CYP1A1 1294/4885CYP1A2 2054/4885CYP1B1 2149/4885 |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | CYP1A1 68/4885CYP1A2 35/4885CYP1B1 56/4885 |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | CYP1A1 1701/4885CYP1A2 2110/4885CYP1B1 1845/4885 |
| US-20050124652-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | CYP1A1 3026/4885CYP1A2 3707/4885CYP1B1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.